Researchers at Ben-Gurion University of the Negev (BGU) have identified how two different classes of medication—the GLP-1 receptor agonist semaglutide and the anti-inflammatory drug colchicine—act on the heart to prevent the development of Atrial Fibrillation (AF). The study, published in Europace, provides a clearer biological map of how these drugs protect the heart's structure and electrical signaling, potentially offering new ways to treat patients before AF takes hold.